Valuation: Epigenomics AG

Market Cap 763K 851K 697K 637K 1.2M 79.97M 1.24M 8.4M 3.35M 42.67M 3.19M 3.12M 135M P/E 2024
-0.29x
P/E 2025 -2.51x
Enterprise Value 11.73M 13.08M 10.72M 9.79M 18.44M 1.23B 19.02M 129M 51.52M 656M 49.09M 48.04M 2.07B EV / Sales 2024
-
EV / Sales 2025 490x
Free-Float
67.04%
Yield 2024 *
-
Yield 2025 -
1 day-1.14%
1 month-4.92%
3 months-5.43%
6 months-6.95%
Current year-3.33%
1 week 0.87
Extreme 0.87
0.88
1 month 0.87
Extreme 0.87
1.19
Current year 0.84
Extreme 0.84
1.56
1 year 0.84
Extreme 0.84
1.59
3 years 0.5
Extreme 0.5
2.65
5 years 0.5
Extreme 0.5
18.18
10 years 0.5
Extreme 0.5
1,187.36
Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal 55 01/02/2024
Director TitleAgeSince
Chairman 58 01/03/2023
Director/Board Member 55 01/06/2020
Director/Board Member 56 05/02/2024
Date Insider Type Main position Quantity % Market Cap. Importance
12/29/22 A Buy

Chief Financial Officer

2,000 0.0122%
9/7/21 A Sell

Director

7,790 0.0637%
2/1/21 A Buy

Chairman

6,355 0.1079%
Change 5-day change 1-year change 3-year change Capi.($)
-1.14%0.00%-2.25%-65.20% 856K
-4.83%+3.51%+53.62%+61.75% 65.94B
-1.34%+2.98%+24.79%+100.18% 56.53B
+0.02%+1.07%+10.63%+76.66% 56.88B
+5.09%+9.89%+22.45%+107.48% 46.49B
+2.62%+1.68%+28.91%+37.01% 44.8B
+8.24%+0.51%+213.26%+792.66% 41.59B
-1.86%+10.13%+26.82%+53.22% 35.35B
-2.97%-9.84%+88.86%+76.17% 33.29B
-2.18%+7.06%+36.06%-4.95% 24.92B
Average +0.16%+2.93%+50.32%+123.50% 40.58B
Weighted average by Cap. +0.21%+3.40%+53.12%+142.96%

Financials

2024 2025
Net sales - 24K 26.76K 21.93K 20.02K 37.72K 2.52M 38.91K 264K 105K 1.34M 100K 98.29K 4.24M
Net income -3.35M -3.74M -3.06M -2.8M -5.27M -351M -5.43M -36.93M -14.72M -187M -14.03M -13.73M -592M -314K -350K -287K -262K -494K -32.91M -509K -3.46M -1.38M -17.56M -1.31M -1.29M -55.44M
Net Debt 10.46M 11.66M 9.55M 8.72M 16.43M 1.1B 16.95M 115M 45.92M 585M 43.75M 42.82M 1.85B 10.97M 12.23M 10.02M 9.15M 17.24M 1.15B 17.78M 121M 48.17M 613M 45.9M 44.91M 1.94B
Projected Income Statement - Annual - Epigenomics AG
Logo Epigenomics AG
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Employees
2
Date Price Change Volume
06/11/26 €0.8700 -1.14% 108
05/11/26 €0.8800 +1.15% 6
04/11/26 €0.8700 -0.57% 0
03/11/26 €0.8750 +0.57% 1
02/11/26 €0.8700 0.00% 0

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Epigenomics AG